ClinicalTrials.gg
Not yet recruitingNCT07950046Updated Nov 20, 2026

High- Versus Low-Density PASCAL Laser Treatment for Proliferative Diabetic Retinopathy

An interventional study of High-Density Single-Session PASCAL Panretinal Photocoagulation and Low-Density Single-Session PASCAL Panretinal Photocoagulation in Proliferative Diabetic Retinopathy (PDR), sponsored by Khyber Girls Medical College. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Khyber Girls Medical College · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare the effects of high-density and low-density single-session Pattern Scan Laser (PASCAL) panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR).

Panretinal photocoagulation is a standard treatment for proliferative diabetic retinopathy. However, the number of laser spots applied during a single treatment session varies in clinical practice. This study will investigate whether applying a higher number of laser spots in one session is as safe and effective as applying a lower number of spots, particularly regarding changes in central macular thickness.

Eligible patients with proliferative diabetic retinopathy who have not previously received PRP will be randomly assigned to one of two groups. The low-density group will receive 2,200-3,000 laser spots, while the high-density group will receive 3,200-4,000 laser spots using the PASCAL laser system in a single session.

Central macular thickness will be measured using optical coherence tomography (OCT) before treatment and four weeks after treatment. The main purpose is to determine whether high-density PRP is not inferior to low-density PRP in terms of changes in central macular thickness. Visual acuity and treatment-related adverse effects will also be assessed.

The findings may help determine whether a higher number of laser spots can be safely delivered in a single PASCAL PRP session without causing an unacceptable increase in macular thickness.

02

Conditions studied

  • Proliferative Diabetic Retinopathy (PDR)

Browse trials for

03

In context

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

This study's planned enrollment of 144 is above the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Khyber Girls Medical College is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Adults aged ≥ 18 years

      • Type 1 or type 2 diabetes mellitus
      • Treatment-naïve PDR with no DME on OCT
      • BCVA better than or equal to 6/60
      • Baseline CMT \<300 µm on Spectralis SD-OCT (central 1 mm ETDRS circle), with no intraretinal or subretinal fluid.
      • Adequate pupil dilation and media clarity to perform OCT and laser photocoagulation

Exclusion criteria

Exclusion Criteria:

  • Other coexisting retinal eye diseases (ARMD, Retinal Vein Occlusion, Uveitis, tractional retinal detachments involving or threatening macula).
  • Any previous retinal laser, anti-VEGF, or intravitreal/suprachoroidal in the study eye.
  • History of any intraocular surgery less than 6 months or Yag Capsulotomy less than 3 months in the study eye.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    Group A

    Procedure: High-Density Single-Session PASCAL Panretinal Photocoagulation

  • Active comparator
    Group B

    Procedure: Low-Density Single-Session PASCAL Panretinal Photocoagulation

Interventions

  • ProcedureHigh-Density Single-Session PASCAL Panretinal Photocoagulation

    Participants will undergo single-session panretinal photocoagulation (PRP) using the PASCAL pattern scan laser system. A total of 3,200-4,000 laser spots will be applied to the peripheral retina

  • ProcedureLow-Density Single-Session PASCAL Panretinal Photocoagulation

    Participants will undergo single-session panretinal photocoagulation (PRP) using the PASCAL pattern scan laser system. A total of 2,200-3,000 laser spots will be applied to the peripheral retina.

06

What researchers measure

Primary outcomes

  1. Change in Central Macular Thickness

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 12 months is below that.

Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07950046
Lead sponsor
Khyber Girls Medical College
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion